Clinical and Experimental Experience with Factor Xa Inhibitors
- 1 January 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in American Journal of Cardiovascular Drugs
- Vol. 4 (6), 379-384
- https://doi.org/10.2165/00129784-200404060-00006
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) studyJournal of the American College of Cardiology, 2004
- Fondaparinux SodiumDrugs, 2004
- Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole bloodThrombosis and Haemostasis, 2004
- From Vulnerable Plaque to Vulnerable PatientCell Metabolism, 2003
- On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasmaBlood Coagulation & Fibrinolysis, 2003
- Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit modelThrombosis and Haemostasis, 2003
- Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy VolunteersCirculation, 2002
- Factor Xa Releases Matrix Metalloproteinase-2 (MMP-2) From Human Vascular Smooth Muscle Cells and Stimulates the Conversion of Pro–MMP-2 to MMP-2Circulation Research, 2002
- First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary DiseaseCirculation, 2002
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001